Ipsen Acquires Global Rights to an Antibody-Drug Conjugate Developed by Simcere Zaiming

Financial Details of the Agreement

Under the terms of the agreement, Simcere Zaiming could receive up to $1.06 billion, the company reports. This amount includes an upfront payment, milestone payments contingent upon reaching certain development stages, as well as regulatory and commercial milestones. Tiered royalties on sales are also planned, subject to the success of clinical development and the necessary regulatory approvals. Ipsen will take over the responsibility for manufacturing the product after a technology transfer, as well as all development activities outside Greater China, including Phase I preparation and regulatory submissions.

Target and Mechanism of Action

SIM0613 targets the LRRC15 protein, which is widely expressed on various types of tumors and cancer-associated fibroblasts, but its expression remains limited on normal cells, according to the press release. The mechanism of action involves the internalization of the conjugate after binding to the LRRC15 protein, allowing the release of a cytotoxic payload that destroys cancer cells while sparing healthy cells. The drug candidate is designed to penetrate deeply into tumors and cancer-associated fibroblasts, which has led to significant tumor regressions in several in vivo preclinical models, the group reports.

Strategic Implications for Ipsen

This acquisition is part of Ipsen's strategy to expand its early-stage product portfolio in the field of oncology. According to the group, more than 20 programs have been added to its early-stage research and development portfolio since 2020. SIM0613 was developed using Simcere Zaiming's exclusive antibody-drug conjugate development platform, a subsidiary of Simcere Pharmaceutical Group Limited. Ipsen focuses on three main therapeutic areas: oncology, rare diseases, and neuroscience, and markets its products in over 100 countries.